COMPASS Pathways plc (CMPS): Total Liabilities
$263.20M
As of 2025-12-31
$420.03M
As of 2026-06-30
+154.2%
3-year compound annual growth
+107.2%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $263.20M | +346.3% | 2026-03-24, Balance as of period end |
| 2024-12-31 | $58.97M | +17.4% | 2026-03-24, Balance as of period end |
| 2023-12-31 | $50.24M | +213.7% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $16.01M | -2.9% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $16.49M | +139.1% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $6.89M | -71.1% | 2022-02-24, Balance as of period end |
| 2019-12-31 | $23.87M | n/a | 2021-03-09, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | 2025-12-31 | $263.20M | +346.3% |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $85.96M | -29.1% |
| Siga Technologies Inc (SIGA) | 2025-12-31 | $20.65M | -27.6% |
| Abeona Therapeutics Inc. (ABEO) | 2025-12-31 | $60.35M | -7.0% |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $305.93M | +3.9% |
| Foghorn Therapeutics Inc. (FHTX) | 2025-12-31 | $306.60M | -7.0% |
| Evommune, Inc. (EVMN) | 2025-12-31 | $19.38M | -32.0% |
| Pliant Therapeutics, Inc. (PLRX) | 2025-12-31 | $44.02M | -52.6% |
| Evolus, Inc. (EOLS) | 2025-12-31 | $248.97M | +9.7% |
Compare CMPS, PBYI, SIGA, ABEO side by side · Screen every company in Pharmaceutical Preparations ↗